Poewe Werner, Chaudhuri K Ray, Bergmann Lars, Antonini Angelo
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Institute of Psychiatry, Psychology & Neuroscience at King's College London & King's College Hospital (KCH) NHS Foundation Trust, London, UK.
Neurodegener Dis Manag. 2019 Feb;9(1):39-46. doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14.
To evaluate long-term effects of levodopa-carbidopa intestinal gel on dyskinesia burden.
PATIENTS & METHODS: Posthoc analysis of the GLORIA registry assessed subgroups of advanced Parkinson's disease patients with <4 and ≥4 h/day of levodopa-induced dyskinesia at baseline.
RESULTS & CONCLUSIONS: Mean dyskinesia duration significantly (p < 0.0001) decreased by 3.5 h in patients with ≥4 h baseline dyskinesia; conversely, dyskinesia duration increased by 1.6 h in patients with <4 h baseline dyskinesia. Quality of life improved in both subgroups. Adverse drug reactions occurred at similar rates in both subgroups. Despite increases in levodopa dose, levodopa-carbidopa intestinal gel treatment led to significant and sustained reductions in dyskinesia time, severity and associated pain in advanced Parkinson's disease patients with high baseline dyskinesia burden.
评估左旋多巴-卡比多巴肠凝胶对异动症负担的长期影响。
对GLORIA注册研究进行事后分析，评估了基线时左旋多巴诱导的异动症每天<4小时和≥4小时的晚期帕金森病患者亚组。
基线异动症≥4小时的患者，平均异动症持续时间显著（p<0.0001）减少了3.5小时；相反，基线异动症<4小时的患者，异动症持续时间增加了1.6小时。两个亚组的生活质量均有所改善。两个亚组的药物不良反应发生率相似。尽管左旋多巴剂量增加，但左旋多巴-卡比多巴肠凝胶治疗使基线异动症负担较高的晚期帕金森病患者的异动症时间、严重程度及相关疼痛显著且持续减少。
